Nrf2 inhibition affects cell cycle progression during early mouse embryo development

Ying LIN1, 2*, Liu-Cai SUI1*, Rong-Hua WU1*, Ru-Jun MA1, Hai-Yan FU1, Juan-Juan XU1, Xu-Hua QIU1 and Li CHEN1

1) Reproductive Medical Center, Jinling Hospital, Clinical School of Medical College, Nanjing University, Jiangsu 210002, People’s Republic of China
2) School of Life Sciences, Nanjing Normal University, Jiangsu, People’s Republic of China

Abstract. Brusatol, a quassinoid isolated from the fruit of Bruceajavanica, has recently been shown to inhibit nuclear factor erythroid 2-related factor 2 (Nrf2) via Keap1-dependent ubiquitination and proteasomal degradation or protein synthesis. Nrf2 is a transcription factor that regulates the cellular defense response. Most studies have focused on the effects of Nrf2 in tumor development. Here, the critical roles of Nrf2 in mouse early embryonic development were investigated. We found that brusatol treatment at the zygotic stage prevented the early embryo development. Most embryos stayed at the two-cell stage after 5 days of culture (P < 0.05). This effect was associated with the cell cycle arrest, as the mRNA level of cyclin B decreased at the two-cell stage after brusatol treatment. The embryo development potency was partially rescued by the injection of Nrf2 CRISPR activation plasmid. Thus, brusatol inhibited early embryo development by affecting Nrf2-related cell cycle transition from G2 to M phase that is dependent on cyclin B-CDK1 complex.

Key words: Brusatol, Cell cycle, Early embryo, Nrf2

Materials and Methods

Mice

Kunming mice were used in the present study. All experiments were approved by the Animal Care and Use Committee of Nanjing Jinling Hospital and performed in accordance with the institutional guidelines. The mice were housed in 12-h light/dark cycles, with free access to food and water.
Antibodies and chemicals
A rabbit polyclonal anti-Nrf2 antibody (ab137550) was purchased from Abcam (Cambridge, MA, USA). Fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit IgG was obtained from Thermo Fisher Scientific (Rockford, IL, USA). Brusatol (14907-98-3) was procured from Shanghai Tauto Biotech Co (Shanghai, China).

Zygote collection and culture
After 46–48 h of 10 IU pregnant mare’s serum gonadotropin (PMSG) injection, mice (6–8-week old) were injected with human chorionic gonadotrophin (HCG) and immediately mated with male mice. Eighteen hours later, the zygotes were harvested from oviduct ampulla. The enclosed cumulus cells were removed by repeated pipetting and the zygotes were harvested from oviduct ampulla. The enclosed cumulus cells were removed by repeated pipetting and the zygotes cultured in cleavage medium (CM, Quinn’s 1026, SAGE, USA) supplemented with 10% serum protein substitute (SPS; Quinn’s 3001, SAGE) and paraffin oil at 37°C under 5% CO₂.

The embryos were transferred to blastocyst medium (BM, Quinn’s 1029, SAGE) supplemented with 10% SPS (Quinn’s 3001, SAGE) at the four-cell phase and collected at different time points for the subsequent assays.

Brusatol treatment
A solution of brusatol in dimethyl sulfoxide (DMSO, 1 mM) was diluted in CM to 20, 50, 100 or 200 nM concentration. The mouse embryos were cultured in this medium and used for immunofluorescence microscopy and western blot analysis. The controls were cultured in fresh CM with DMSO.

Activation of Nrf2
The cytoplasm of pronucleus-stage zygotes was microinjected with Nrf2 CRISPR activation plasmid (sc-421869-ACT; Santa Cruz Biotechnology, San Jose, CA, USA) to induce Nrf2 protein overexpression. The plasmid was diluted with nuclease-free water to obtain a stock concentration of 0.04 μg/μl, and 2.5 pl plasmid was injected into the zygotes with a Narishige microinjector. The control embryos were microinjected with phosphate-buffered saline (PBS). After injection, all the embryos were cultured in brusatol-treated CM.

Quantitative real-time polymerase chain reaction (qRT-PCR)
Around 50 embryos from each group were used to extract total RNA using an RNA queous-Micro kit (Ambion, TX, USA) and cDNA was quantified by qRT-PCR using a Roche Light Cycler 96 Real-time PCR system (F. Hoffmann-La Roche, Basel, Switzerland). The fold change in the gene expression was estimated using ΔΔCt method with the housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), as the internal control. Primer sequences are listed in Table 1.

Western blotting analysis
A total of 100 embryos were lysed in Laemmli sample buffer containing protease inhibitors. The samples were heat denatured for 5 min at 100°C, separated on 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel, and transferred onto a polyvinylidene fluoride membrane. The membrane was blocked in TBST (Tris-buffered saline containing 0.1% Tween 20) and 5% nonfat milk for 1 h. After incubation, the membrane was overnight treated at 4°C with primary antibodies as follows: rabbit anti-Nrf2 antibody (1:1000), rabbit anti-UCHL1 antibody (1:1000), and anti-actin antibody (1:2000). After three TBST washes, the membrane was incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies for 1 h at 20°C and processed using an enhanced chemiluminescence (ECL) Plus western blotting detection system.

Immunofluorescence and fluorescence microscopy
For Nrf2 staining, embryos were fixed with 4% paraformaldehyde for 30 min and permeabilized with 0.5% Triton X-100 for 20 min. After 1-h blocking in 1% bovine serum albumin (BSA)-supplemented PBS, the samples were incubated overnight at 4°C with anti-Nrf2

Table 1. Primer sequences and product sizes used for qRT-PCR

| Genes     | GeneBank accession no. | Primers | Primer sequences | Amplicon size (bp) |
|-----------|------------------------|---------|------------------|--------------------|
| GAPDH     | NM_008084.3            | Forward | 5'-CTTTGTCAAGCTCATTTCCTTG-3' | 133                |
|           |                        | Reverse | 3'-TCTTGGCTCAAGCTCATTTCCTTG-5' |                |
| Cyclin B  | NM_172301.3            | Forward | 5'-CTGACCCAAACCTCCTAGTG-3' | 250                |
|           |                        | Reverse | 3'-CTCTGCTATTAGCCAGTAAAATAG-5' |                |
| CDK1      | NM_007659.3            | Forward | 5'-TGCAAGGACTAACAAGAACC-3' | 142                |
|           |                        | Reverse | 3'-GCCAGGGGGGAGGCTGCTC-5' |                |
| HO-1      | NM_010442.2            | Forward | 5'-ACAGAGGAAACAAGAAACCAG-3' | 136                |
|           |                        | Reverse | 3'-GAGTGTGGGTAGCTAGTG-5' |                |
| GCLC      | NM_010295.2            | Forward | 5'-ACCATACCTTCATTCGCCAG-3' | 148                |
|           |                        | Reverse | 3'-TTCTTGTGAGTACCCAAAGG-5' |                |
| SOD1      | NM_011434.1            | Forward | 5'-TGTTGCTGACTAAGATCGTGTTG-3' | 137                |
|           |                        | Reverse | 3'-TCCAGAGCTTTCCAGCTTTTG-5' |                |
| elf-1a    | NM_010120              | Forward | 5'-AAGAAGCTGAAAGCGCTATG-3' | 170                |
|           |                        | Reverse | 3'-CAGAAACCTTGGAGAAGGAC-5' |                |
| hsp70.1   | NM_010478              | Forward | 5'-TGCTGACCCAGGTGTACGAG-3' | 204                |
|           |                        | Reverse | 3'-CGTGGTGATGGTGATCTTG-5' |                |
antibody. The embryos were washed thrice in PBS and labeled with a goat-anti rabbit IgG at room temperature for 1 h. Hoechst 33342 (blue) was used for chromosome staining. The embryo samples were mounted on an anti-fade medium (Vectashield, Burlingame, CA, USA) and examined under a fluorescence microscope (IX3-SVR, Olympus, Japan).

Labeling with EdU for DNA replication

Two-cell embryos were labeled in vitro with EdU to confirm their arrest phase. EdU is a thymidine analogue and may substitute thymine (T) into the cells during DNA synthesis. EdU is assessed based on the direct and accurate detection of DNA replication activity by Apollo® fluorescent dye. The EdU-specific reaction is widely used in cell proliferation [18, 19]. Two-cell embryos were treated with 25 μM EdU 18 h after insemination and cultured until 2.5 days after the embryo development [20]. About 50 arrested two-cell embryos were collected and EdU-labeled embryos were stained using an EdU detection kit (RiboBio, Guangzhou, China).

Statistical analysis

Statistical comparisons were made with Student’s t-test and analysis of variance (ANOVA) when appropriate. Quantitative data were analyzed with Prism 5 software (GraphPad, San Diego, CA, USA). Data are presented as means ± standard deviation (SD), unless otherwise indicated. Values of P < 0.05 were considered as statistically significant.

Results

Expression pattern of Nrf2 during mouse early embryonic development

The zygotes harvested from the oviduct were cultured for 24, 48, 72 and 96 h to obtain two-cell, four-cell, morula, and blastocyst stage embryos, respectively. We explored the localization of Nrf2 at different stages in early embryos by immunofluorescence staining and found that Nrf2 was expressed in the cytoplasm and accumulated in the nucleus from the two-cell stage up to the blastocyst stage (Fig. 1). Moreover, immunofluorescence staining verified the specificity of Nrf2 antibody (data not shown).

Brusatol treatment prevented early embryonic development

To evaluate the impact of Nrf2 on embryonic development, the embryos at the zygote phase were treated with various concentrations...
of brusatol (20, 50, 100 and 200 nM) for 0, 24, 48, 72 and 96 h. The control group was treated with equivalent DMSO. Images were recorded by a camera on a stereomicroscope. As shown in Figs. 2A and 2B, most embryos underwent cleavage and developed into two-cell stage after 24 h. After 48 h, the percentage of embryos developing into four-cell stage was significantly decreased in groups treated with 20, 50, 100, and 200 nM brusatol as compared with the control group. None of the embryos developed into four-cell stage in 200 nM brusatol treatment group. After 72 h, no significant difference was observed between control and 20 nM brusatol treatment group, but a significant difference was observed with 50 nM brusatol treatment group. However, no embryo had entered this stage in 100 nM brusatol treatment group. After 96 h, approximately 19.25 ± 13.1% blastocysts were observed in 50 nM treatment group as compared with 77.5 ± 3.5% in the control group (P < 0.05), whereas 68 ± 1.8% blastocysts were observed in 20 nM treatment group (P > 0.05). These results suggest that brusatol treatment resulted in the failure of early embryonic development in a dose-dependent manner. The concentration of 50 nM brusatol was selected for subsequent experiments.

Brusatol down-regulated Nrf2 expression

We examined the expression of Nrf2 in mouse early embryo by immunofluorescence staining and found that the fluorescence intensity of Nrf2 was significantly decreased in brusatol-treated group as compared with the control group (Figs. 3A and 3B). This observation was further confirmed by western blot analysis (Figs. 3C and 3D). In addition, qRT-PCR analysis indicated the decreased expression of Nrf2 (Fig. 3E). The intensity of Nrf2 protein was significantly decreased in brusatol-treated group (0.785 ± 0.13%) as compared with the control group (P < 0.05). To test the correlation between brusatol-induced Nrf2 reduction and ubiquitin-proteasome system, UCHL1 levels were determined by western blot analysis (Figs. 3D and 3E). Brusatol treatment led to a significant reduction in UCHL1.

Brusatol treatment decreased mRNA level of Nrf2-mediated antioxidant genes

To determine the mechanism contributing to brusatol-mediated down-regulation of Nrf2, we examined the mRNA expression of Nrf2 and Nrf2 target genes, HO-1, GCLC, and SOD1, by qRT-PCR in control and brusatol-treated groups. Brusatol significantly decreased the level of Nrf2 (Fig. 3C) and relevant antioxidant genes, including HO-1, GCLC, and SOD1 (Fig. 4).

Brusatol treatment decreased the mRNA level of cyclin B, CDK1, eif-1a, and hsp70.1

To investigate the cause of mouse early embryonic cleavage failure, we examined the mRNA expression of cyclin B and CDK1 by qRT-PCR after brusatol treatment of two-cell embryos. As shown in Fig. 5A, the relative expression of cyclin B and CDK1 was markedly decreased upon brusatol treatment as compared with the control group (P < 0.05). After 48 h, the embryos contained integrated nuclear membranes and incorporated EdU, suggestive of their arrest in G2/M phase (Fig. 5B) [21]. We detected the mRNA expression of zygotic gene activation (ZGA)-related genes, eif-1a and hsp70.1 (Fig. 5C) and found that brusatol treatment significantly decreased the expression of eif-1a and hsp70.1 genes (P < 0.05).

Overexpression of Nrf2 by microinjection of Nrf2 CRISPR activation plasmid into the cytoplasm of the zygote partially rescued the embryo development potency

To evaluate if brusatol treatment prevented the mouse embryonic development through Nrf2, we injected the zygote with Nrf2 CRISPR activation plasmid during brusatol treatment and observed the embryonic development (Fig. 6A). The overexpression efficiency of the plasmid was verified by western blot analysis (Figs. 3D and 3E). The relative expression of Nrf2 protein was markedly increased in the Nrf2 activation group as compared with the brusatol-treated group (P < 0.05), similar to the expression of UCHL1. The percentage of embryos at four-cell stage was markedly higher in Nrf2 activation group (42.7 ± 8.3%) as compared with brusatol-treated group (23.3 ± 2.9%; P < 0.05; Fig. 5B), which was similar to that of morula and blastocyst (P < 0.05). These results showed that the overexpression of Nrf2 partially rescued the embryo development potency, suggestive of the effect of brusatol on the mouse embryonic development through Nrf2.

Discussion

Here, we used brusatol to investigate the effects of Nrf2 on mouse early embryonic development. Our results suggest that brusatol exhibited adverse effects on early embryonic development through Nrf2 down-regulation.

We evaluated the localization of Nrf2 during embryonic development. Immunofluorescence staining of Nrf2 in embryos at various developmental stages (from two-cell to morula stage) revealed that Nrf2 primarily accumulated in the cytoplasm, consistent with the reports of a previous study showing Nrf2 accumulation in the cytoplasm of endometrial glandular cells [22]. The expression pattern encouraged us to further investigate the possible roles of Nrf2. The knockdown of Nrf2 expression was shown to inhibit proliferation by inducing apoptosis in various cancer cells, and Nrf2 overexpression resulted in converse phenotypes [23, 24]. However, little is known about the role of Nrf2 in early mouse embryo. To evaluate the effects of Nrf2 on mouse embryonic development, zygotes were pretreated with brusatol. Brusatol down-regulated Nrf2 expression in mouse early embryo, as evident from western blot results. In addition, brusatol prevented the early embryo cleavage at concentrations from 50 nM, resulting in cell cycle arrest. Studies have shown that Nrf2-knockout mice are viable and may mature to give birth; however, these mice show accelerated ovarian failure and develop autoimmune dysfunction [25]. This observation indicates that Nrf2 is a transcriptional factor controlling wide spectra of substrates and plays an important role in reproduction.

The transcription factor Nrf2 is involved in redox-sensitive signaling and antioxidant response by activating cytoprotective protein or antioxidant enzymes [26, 27]. Therefore, we detected Nrf2 target genes, including HO-1, GCLC, and SOD1 by qRT-PCR. The decrease in the expression of these genes is indicative of the oxidative stress, suggesting that these genes are likely to be the targets of Nrf2. In addition, Nrf2 degradation is Keap1-dependent; Keap1-Nrf2 interaction is antagonized by ubiquitination pathway. The mechanism underlying brusatol-induced Nrf2 inhibition via ubiquitination pathway is partially confirmed by the decreased expression of UCHL1 protein.
However, several recent studies suggest that Nrf2 knockdown may lead to cell cycle arrest in MHCC-97H cells. In addition, Nrf2 knockout promoted cell cycle arrest in Hep3B cells, while Nrf2 overexpression resulted in antagonistic effects [30]. These results indicate that Nrf2 not only protects the cell from oxidative stress but also maintains the order of cell cycle. Therefore, we examined cyclin B and CDK1 mRNA expressions and found that cyclin B, the G2/M cyclin associated with CDK1 activation, promotes the M-phase entry during embryo cell cycle [31, 32]. We hypothesize that Nrf2 may also be involved in the transcriptional regulation of cyclins in early mouse embryos. Our EdU assay results showed that brusatol induced cell cycle arrest mainly in G2/M phase. Cyclin B and CDK1
Fig. 6. Effects of microinjection of Nrf2 CRISPR activation plasmid in the cytoplasm of the zygote on the embryo development potency. A) Embryos were microinjected with Nrf2 CRISPR activation plasmid in a medium supplemented with brusatol for 24, 48, 72 and 96 h. Nrf2 activation group showed a significant increase in the four-cell stage embryos as compared with brusatol treatment group. B) Microinjection with Nrf2 CRISPR activation plasmid partially rescued the embryo development potency. The embryo development rate from four-cell to blastocyst stage was significantly increased as compared with the embryos treated with brusatol. As shown in Fig. 3C, the expression of Nrf2 protein was increased in Nrf2 activation group as compared with the brusatol treatment group. a, b, and c represent the significant differences in three groups. Original magnification × 200.

mRNA expression were significantly decreased following brusatol treatment as compared with the control group. Furthermore, the onset of ZGA is a critical event for embryonic development [20] and the decreased expression of elf-1α and hsp70.1 genes indicates that Nrf2 inhibition affects ZGA of early mouse embryo. Based on these results, we explored the role of Nrf2 in embryonic development. However, the ultimate function and mechanisms of Nrf2 in mouse early embryonic development require further exploration.

We overexpressed Nrf2 by the microinjection of the zygote and found that the embryo development rates were partially rescued as compared with the brusatol treatment group. These results indicate that Nrf2 promotes the early embryo development and brusatol affects Nrf2 expression. Taken together, our results show that brusatol prevents early embryo development through the down-regulation of Nrf2 and this effect may be mainly dependent on cyclin B-CDK1–associated cell cycle transformation from G2 to M phase. Nrf2 may serve as a new factor affecting embryo cleavage and blastocyst formation and Nrf2 detection may be used as a novel diagnostic and therapeutic approach for assisted reproduction technology.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (grant number 81503655) and Foundation of Jinling Hospital, Clinical School of Medical College, Nanjing University (2014027&2014030).

References

1. Zhang J, Wang Y, Liu X, Jiang S, Zhao C, Shen R, Guo X, Ling X, Liu C. Expression and potential role of microRNA-29b in mouse early embryo development. *Cell Physiol Biochem* 2015; 38: 1178–1187. [Medline] [CrossRef]

2. Zhao N, Zhang Y, Liu Q, Xiang W. Msn2 affects embryo development via mitochondrial dysfunction and apoptosis. *PLoS ONE* 2015; 10: e0125680. [Medline] [CrossRef]

3. Duan X, Chen KL, Zhang Y, Cui XS, Kim NH, Sun SC. ROCK inhibition prevents early mouse embryo development. *Histochem Cell Biol* 2014; 142: 227–233. [Medline] [CrossRef]

4. Li Q, Zhang P, Zhang C, Wang Y, Wu R, Yang Y, Guo X, Huo R, Liu M, Zhou Z, Sha J. DDX3X regulates cell survival and cell cycle during mouse early embryonic development. *J Biomed Res* 2014; 28: 282–291. [Medline] [CrossRef]

5. Wang QC, Liu J, Duan X, Cui XS, Kim NH, Xiong B, Sun SC. The Dynamin 2 inhibitor Dynasore affects the actin filament distribution during mouse early embryo development. *J Reprod Dev* 2015; 61: 49–53. [Medline] [CrossRef]

6. Yang QC, Liu J, Duan X, Cui XS, Kim NH, Xiong B, Sun SC. Cyclin A and B functions in the early Drosophila embryo. *Development* 1999; 126: 5505–5513. [Medline] [CrossRef]

7. Stittler LA, Ji JY, Trautmann S, Trusty C, Schubiger G. Cyclin A and B functions in the early Drosophila embryo. *Oncogene* 2014; 12: 482–488. [Medline] [CrossRef]

8. Ryoo IG, Kim G, Choi BH, Lee SH, Kwak MK. Involvement of NRF2 signaling in doxorubicin resistance of cancer stem cell-enriched colonospheres. *BioMed Res (Seoul)* 2016; 24: 482–488. [Medline] [CrossRef]

9. Goldberg LL, Lee J, Goad F, Klijn C, Schamb A, Reeder J, Daemen A, Bakalarzki CE, Holcomb T, Shames DS, Hartmaier RJ, Chmielecki J, Seshagiri S, Gentleman R, Stoke D. Recurrent loss of NFE2L2 Exon 2 Is a mechanism for Nrf2 pathway activation in human cancers. *Cell Reports* 2016; 16: 2605–2617. [Medline] [CrossRef]
12. Zou Y, Hu M, Lee J, Namibr SM, Garcia V, Bao Q, Chan JY, Dai G. Nrf2 is essential for timely M phase entry of replicating hepatocytes during liver regeneration. *Am J Physiol Gastrointest Liver Physiol* 2015; 308: G262–G268. [Medline] [CrossRef]

13. Liu Y, Liu H, Cao H, Song R, Zhang W, Zhang W. PKH26OPT mediates promyelocyte proliferation via Nrf2-regulated cell cycle progression and apoptosis. *Oncof Rep* 2015; 34: 3288–3296. [Medline] [CrossRef]

14. Mata-Greenwood E, Cuendet M, Sher D, Gustin D, Stock W, Pezzuto JM. Brusatol-mediated induction of leukemic cell differentiation and G1 arrest is associated with down-regulation of c-myc. *Leukemia* 2002; 16: 2275–2284. [Medline] [CrossRef]

15. Olayanju A, Copp JM, Bryan HK, Edge GT, Sisson RL, Wong MW, Lai ZQ, Lin ZX, Dunn K, Sanderson CM, Alghanem AM, Cross MJ, Ellis EC, Ingelman-Sundberg M, Malik HZ, Kitteringham NR, Goldenberg CE, Park BK. Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2. *Free Radic Biol Med* 2015; 78: 202–212. [Medline] [CrossRef]

16. Sanchez-Diaz PC, Chang JC, Moses ES, Dao T, Chen Y, Hung JV. Ubiquitin carboxyl-terminal esterase L1 (UCHL1) is associated with stem-like cancer cell functions in pediatric high-grade glioma. *PLoS ONE* 2015; 10: e0176879. [Medline] [CrossRef]

17. Bao L, Wu J, Dodson M, Rojo de la Vega EM, Ning Y, Zhang Z, Yao M, Zhang DD, Xu C, Yi X. ABCF2, an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells. *Mol Cancerg* 2015; 56: 1543–1555. [Medline] [CrossRef]

18. Warren M, Paskarzynk K, Chapman SC. Chick embryo proliferation studies using EdU labeling. *Dev Dyn* 2009; 238: 944–949. [Medline] [CrossRef]

19. Cinquin O, Crittenden SL, Morgan DE, Kimble J. Progression from a stem cell-like state to early differentiation in the C. elegans germ line. *Proc Natl Acad Sci USA* 2010; 107: 2048–2053. [Medline] [CrossRef]

20. Shin SW, Tokoro M, Nishikawa S, Lee HH, Hatanaka Y, Nishihara T, Amano T, Anazl M, Kato H, Miti, T, Kishigami S, Saeki K, Hosoi Y, Iritani A, Matsumoto K. Inhibition of the ubiquitin-proteasome system leads to delay of the onset of ZGA gene expression. *J Reprod Dev* 2010; 56: 655–663. [Medline] [CrossRef]

21. Buffett MG, Schindler K, Schultz RM. Overexpression of CDC41B causes mitotic arrest and inhibits ploidy genome activation in mouse preimplantation embryos. *Cell Cycle* 2009; 8: 3904–3913. [Medline] [CrossRef]

22. Wang Y, Wang Y, Zhang Z, Park JY, Gao D, Liao H, Yi X, Zheng Y, Zhang D, Chambers SK, Zheng W. Mechanism of progestin resistance in endometrial precursor/cancer through Nrf2-AR1/1 pathway. *Oncotarget* 2016; 7: 10363–10372. [Medline] [CrossRef]

23. Zhang M, Zhang C, Zhang L, Yang Q, Zhou S, Wen Q, Wang J. Nrf2 is a potential prognostic marker and promotes proliferation and invasion in human hepatocellular carcinoma. *BMC Cancer* 2015; 15: 531. [Medline] [CrossRef]

24. Ma JQ, Tuersun H, Jiao SJ, Zheng JH, Xiao JB, Hasim A. Functional role of Nrf2 in cervical carcinogenesis. *PLoS ONE* 2015; 10: e0133876. [Medline] [CrossRef]

25. Hu X, Roberts JR, Apopu PL, Kan YW, Ma Q. Accelerated ovarian failure induced by 4-vinyl cyclohexene diepoxide in Nrf2 null mice. *Mol Cell Biol* 2006; 26: 940–954. [Medline] [CrossRef]

26. Fratta Pasini AM, Ferrari M, Stranieri C, Vallerio P, Mozini C, Garbin U, Zambon G, Cominacini L. Nrf2 expression is increased in peripheral blood mononuclear cells derived from mild-moderate ex-smoker COPD patients with persistent oxidative stress. *Int J Chron Obstruct Pulmon Dis* 2016; 11: 1733–1743. [Medline] [CrossRef]

27. Saddawi-Konekla R, Seelige R, Gross ET, Levy E, Searles SC, Washington A Jr, Santosa EK, Liu B, Osullivan TE, Harismendy O, Bui JD. Nrf2 induces IL-17D to mediate tumor and virus surveillance. *Cell Reports* 2016; 16: 2348–2358. [Medline] [CrossRef]

28. Hochmuth CE, Bibeau B, Bohmann D, Jasper H. Redox regulation by Keap1 and Nrf2 controls intestinal stem cell proliferation in Drosophila. *Cell Stem Cell* 2011; 8: 188–199. [Medline] [CrossRef]

29. Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, Herman JG, Baylin SB, Sidransky E, Brock M, Biswal S. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. *PLoS Med* 2006; 3: e420. [Medline] [CrossRef]

30. Liu D, Zhang Y, Wei Y, Liu G, Liu Y, Gao Q, Zou L, Zeng W, Zhang N. Activation of AKT pathway by Nrf2/PDGFA feedback loop contributes to HCC progression. *Oncotarget* 2016; 7: 65389–65402. [Medline] [CrossRef]

31. El Bika M, Laskowska-Kuszk B, Koryto M, Dudka D, Prigent C, Tassan JP, Kloc M, Polanski Z, Borsuk E, Kubiak JJ. CDC6 controls dynamics of the first embryonic M-phase entry and progression via CDK1 inhibition. *Dev Biol* 2014; 396: 67–80. [Medline] [CrossRef]

32. Pushpavalli SN, Sarkar A, Bag I, Hunt CR, Ramaiah MJ, Pandita TK, Bhadra U, Pal-Bhadra M. Argonaute-1 functions as a mitotic regulator by controlling Cyclin B during Drosophila early embryogenesis. *FASEB J* 2014; 28: 655–666. [Medline] [CrossRef]